Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Darunavir:Susc:Pt:Isolate:OrdQn:Phenotyping

Known as: Darunavir:Susc:Pt:Isolato:OrdQn:Fenotipizzazione, Darunavir:Susceptibility:Point in time:Isolate:Quantitative or Ordinal:Phenotyping, Darunaviir:Susc:Pt:Is:OrdQn:Fenotüpiseerimine 
 
National Institutes of Health

Related topics

Related topics

3 relations
Isolate - microorganismPhenotype determinationdarunavir

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Pooled resistance analyses of darunavir once-daily regimens and formulations across 10 clinical studies of treatment-naïve and treatment-experienced patients with human immunodeficiency virus-1…
BACKGROUND The efficacy and high barrier to resistance of darunavir have been demonstrated across diverse populations with HIV-1… Expand
Is this relevant?
2019
2019
Efficacy and safety of dolutegravir plus boosted-darunavir dual therapy among highly treatment-experienced patients.
BACKGROUND Dual therapies decrease toxicity, pill-burden, and treatment-associated cost. The combination of high genetic barrier… Expand
Is this relevant?
2017
2017
HIV-1 resistance rarely observed in subjects using darunavir once-daily regimens across clinical studies
Background: Darunavir 800 mg once daily (QD) is indicated for HIV-1–infected treatment-naïve and treatment-experienced (without… Expand
Is this relevant?
2016
2016
In-vivo bioavailability and lymphatic uptake evaluation of lipid nanoparticulates of darunavir
Abstract Darunavir is effective against wild-type and PI-resistant HIV, and has an oral bioavailability of 37%. It needs to be… Expand
Is this relevant?
Highly Cited
2014
Highly Cited
2014
Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial
BackgroundCobicistat is an alternative pharmacoenhancer to ritonavir. In healthy volunteers, darunavir exposure was comparable… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Review
2014
Review
2014
Pharmacokinetics and pharmacodynamics of boosted once-daily darunavir.
The ability to dose antiretroviral agents once daily simplifies the often complex therapeutic regimens required for the… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
Is this relevant?
2010
2010
Impact of the Background Regimen on Virologic Response to Etravirine: Pooled 48-Week Analysis of DUET-1 and -2
Abstract Purpose: This subgroup analysis of the phase 3 DUET trials examined the impact of the background regimen on virologic… Expand
Is this relevant?
2009
2009
Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC.
AIMS ABCB1, some ABCCs and SLCOs have been reported to affect the intracellular accumulation of various protease inhibitors in… Expand
  • figure 1
  • figure 2
Is this relevant?
2008
2008
Effect of baseline viral susceptibility on response to darunavir/ritonavir versus control protease inhibitors in treatment-experienced HIV type 1-infected patients: POWER 1 and 2.
Data from two Phase IIb trials, POWER 1 and 2 (TMC114-C213 and C202), were pooled to examine the effect of baseline viral… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE